Remifentanil or dexmedetomidine for monitored anesthesia care during cataract surgery under topical anesthesia

Abstract

Cataract surgery is usually performed under topical anesthesia. The procedure is quick and simple to perform and topical anesthesia avoids the potential hazards of a nerve block. However, topical anesthesia may not provide complete anesthesia and may cause anxiety or uncontrolled and unexpected movement. Monitored anesthesia care (MAC) is intended to provide anxiety relief, patient comfort, and safety during eye surgery. Propofol, benzodiazepines, and opioids have been used for sedation during cataract surgery [1]. However each of these drugs causes respiratory depression, hypoxemia, and apnea. The adverse respiratory complications of these drugs may impede the patient’s cooperation during surgery and increase the need for a sedative drug that can be used safely during MAC. Dexmedetomidine is a central α2 agonist that can be titrated to the desired sedation level without significant respiratory depression and has been used as a primary sedative drug for various surgical and diagnostic procedures [2]. Unlike other opioids, remifentanil, which is a μ-opioid receptor agonist, has a short elimination half life of 3-10 min and a short context sensitive half life of 3-5 min. These properties of remifentanil suggest that it may be useful for MAC either combined with propofol or alone [3]. The aim of this study was to compare dexmedetomidine with remifentanil during cataract surgery in patients under topical anesthesia. The protocol was approved by the Institutional Review Board of our hospital, and all patients provided written informed consent. Eighty American Society of Anesthesiology physical status class 1-3 patients (age, 60-80 years), who were scheduled for elective cataract surgery under topical anesthesia, were enrolled in this study. Patients were randomized to receive either dexmedetomidine (group D) or remifentanil (group R). Group D patients received an infusion of 0.5 μg/kg dexmedetomidine over 10 minutes followed by a main tenance infusion at a rate of 0.2 μg/kg/hr. Group R patients received remifentanil by target controlled infusion to reach a 1 ng/ml target effect site concentration (Cet). Heart rate (HR), systolic blood pressure, diastolic blood pressure, mean arterial pressure (MAP), respiratory rate (RR), oxygen saturation (SpO2), bispectral index monitor (BIS) and end tidal (ET)CO2 were recorded before infusion (baseline), after the start of infusion, and every 5 minutes after infusion. The degree of sedation was evaluated using the Ramsay sedation scale by an anesthesiologist who was unaware of the type of sedative used. The satisfaction of the patients and surgeon was assessed immediately after surgery using a 7-point Likert-like verbal rating scale. Recovery time was the interval from stopping the infusion to the time when the patient’s Ramsay sedation score was 2. Demographic variables were compared using the t-test. Physiological data were analyzed by repeated-measures analysis of variance. The chi-square test was used to compare the sedation and satisfaction scores. No differences in baseline characteristics were observed between the groups. Significantly lower MAP, ETCO2, and higher RR were observed over time in group D compared with those in group R. No significant differences in HR or SpO 2 were observed between the groups. BIS scores decreased at 10, 15, and 20 minutes after infusion, but no significant differences in BIS scores were observed between the groups. More patients